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Abstract
The introduction of new cytotoxic substances as well 
as agents that target vascular endothelial growth factor 
(VEGF) and epidermal growth factor receptor (EGFR) 
signaling has improved clinical outcome of patients with 
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metastatic colorectal cancer (mCRC). In this review 
we summarize the most relevant clinical data on VEGF 
and EGFR targeting regimens in mCRC. The effects 
of available treatment strategies for mCRC are often 
temporary, with resistance and disease progression de-
veloping in most patients. Thus, new treatment strate-
gies are urgently needed. Some GI peptides including 
gastrin and gastrin releasing peptide, certain growth 
factors such as insulin-like growth factor-Ⅰ and Ⅱ and 
neuropeptides such as growth hormone releasing hor-
mone (GHRH) are implicated in the growth of CRC. Ex-
perimental investigations in CRC with antagonistic ana-
logs of bombesin/gastrin-releasing peptide, GHRH, and 
with cytotoxic peptides that can be targeted to peptide 
receptors on tumors, are summarized in the second 
part of the review. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
Key words: Colorectal cancer; Targeted treatment; 
Vascular endothelial growth factor; Epidermal growth 
factor receptor; Peptide receptors; Gastrin-releasing 
peptide; Growth hormone releasing hormone; Lutein-
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Core tip: Our review evaluates the most recent clini-
cal data on therapeutic reagents designed to target 
the vascular endothelial growth factor and epidermal 
growth factor receptor signaling pathways in colorec-
tal cancer. As colorectal cancers express receptors for 
bombesin/gastrin-releasing peptide, growth hormone-
releasing hormone, somatostatin as well as luteinizing 
hormone-releasing hormone, we review the implica-
tions of these pathways in the growth of colorectal 
cancers and summarize experimental data and clinical 
studies performed to date with regard to the antiprolif-
erative action of antagonistic peptide analogs of these 
receptors as well as their cytotoxic analogs and their 
status as drug candidates for the treatment of meta-
static colorectal cancer. 
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.3748/wjg.v20.i20.6102
World J Gastroenterol  2014 May 28; 20(20): 6102-6112
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2014 Baishideng Publishing Group Inc. All rights reserved.
Hohla F, Winder T, Greil R, Rick FG, Block NL, Schally AV. 
Targeted therapy in advanced metastatic colorectal cancer: Cur-
rent concepts and perspectives. World J Gastroenterol 2014; 
20(20): 6102-6112  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v20/i20/6102.htm  DOI: http://dx.doi.
org/10.3748/wjg.v20.i20.6102
INTRODUCTION
Worldwide estimates of  new cases of  colorectal cancer 
(CRC) exceed 1.2 million, with more than 600000 deaths 
per year[1]. It is estimated that 20% of  patients with 
CRC have metastatic disease at the time of  diagnosis; 
20%-25% of  patients will experience metastases during 
the course of  the disease thus resulting in a relatively high 
overall mortality rate of  40%-45%[2]. Beside standard 
chemotherapy (CTX) with 5-fluorouracil (5-FU) based 
regimens, the incorporation of  monoclonal antibod-
ies (mAbs) targeting vascular endothelial growth factor 
(VEGF) and epidermal growth factor receptor (EGFR) 
signaling pathways have further broadened the treatment 
options for metastatic colorectal cancer (mCRC) pa-
tients. Although the survival for all patients with mCRC 
has improved significantly, the 5-year survival rates still 
remain low at about 10%, with a median overall survival 
(OS) of  24 mo. Thus, new approaches to the treatment 
of  mCRC are required. Antagonistic analogs of  bombe-
sin/gastrin releasing-hormone (BN/GRP) and growth 
hormone-releasing hormone (GHRH) as well as targeted 
cytotoxic analogs of  luteinizing hormone-releasing hor-
mone (LHRH) and somatostatin (SST), linked to che-
motherapeutic substances, which have been developed 
in our laboratories over the last two decades, have been 
shown to be highly effective in suppressing the prolifera-
tion of  experimental human CRC in vivo and in vitro and 
represent an entirely new class of  antineoplastic agents 
for the treatment of  mCRC. In the first part of  the pres-
ent review the most recent data on currently available 
biological agents that target the VEGF (bevacizumab, 
aflibercept and regorafenib) and EGFR pathways (cetux-
imab and panitumumab) are highlighted. In the second 
part, we summarize experimental studies performed so 
far regarding the antiproliferative action of  antagonists 
of  BN/GRP and GHRH as well as cytotoxic analogs of  
Somatostatin and LHRH against CRC in vitro and in vivo. 
VEGF TARGETING MABS
Bevacizumab
Bevacizumab (Bev), developed in the early 1990s, is a 
recombinant, humanized IgG1 mAb effective against 
all isoforms of  VEGF-A that disrupts their interactions 
with VEGFRs[3]. Preclinical studies have demonstrated 
that Bev exhibits a broad range of  antitumor activity[4]. 
The most relevant clinical studies with Bev in combina-
tion with CTX are summarized in Table 1. In the pivotal 
clinical trial of  Hurwitz et al[5], designated AVF2107, 
patients with untreated mCRC were given a combina-
tion of  irinotecan, bolus 5-FU, leucovorin (LV) (IFL), 
and placebo or a combination of  IFL and Bev (5 mg/kg 
biweekly). The study showed a significant benefit in over-
all response (45% vs 35%, P = 0.004), progression free 
survival (PFS) (10.6 mo vs 6.2 mo, P < 0.001), and overall 
survival (OS) (20.3 mo vs 15.5 mo, P = 0.001) for mCRC 
patients treated with Bev. In another phase 3 clinical trial, 
designated BICC-C, performed by Fuchs et al[6], patients 
with mCRC were randomly assigned to receive one of  
three different irinotecan-containing regiments (irinote-
can plus infusional 5-FU and LV (FOLFIRI), irinotecan 
plus bolus 5-FU/LV (mIFL) and irinotecan plus oral 
capecitabine (CapeIRI) (designated as period 1). After 
a protocol amendment, an additional 117 patients were 
randomly assigned to FOLFIRI plus Bev or mIFL + Bev, 
whereas, due to toxicity concerns, further enrollment of  
CapeIRI was discontinued (designated as period 2). The 
results for both periods 1 and 2 demonstrated that FOL-
FIRI and FOLFIRI+Bev offered superior activity to their 
therapeutic alternatives. Furthermore, patients who re-
ceived FOLFIRI+Bev showed a higher overall response 
rate (47% vs 54.4%), a longer PFS (11.2 mo vs 7.6 mo) 
and median OS (28 mo vs 23.1 mo) compared to FOL-
FIRI alone. The fact that infusional 5-FU showed a sig-
nificant longer PFS compared to the oral 5-FU prodrug, 
capecitabine (7.6 vs 5.8, P = 0.015), led to the recommen-
dation to preferentially use infused 5-FU, instead of  its 
oral prodrug, in combination with irinotecan. However, 
a subsequently performed phase Ⅱ trial which assessed 
the efficacy and safety of  Bev plus oral capecitabine and 
irinotecan or FOLFIRI as first line therapy for patients 
with mCRC found no difference between the oral and 
the infused 5-FU regimen regarding the PFS and OS (9 
mo and 23 mo)[7]. The convincing results obtained by 
phase 3 combination studies with irinotecan and Bev led 
study designers to consider whether Bev could enhance 
the effect of  any CTX regimen. However, subsequent tri-
als with oxaliplatin-based regimens produced less robust 
differences[8-10]. In the Phase-Ⅲ trial, NO16966, by Saltz 
et al[10], the effect of  capecitabine and oxaliplatin (XELOX) 
compared with those of  infused 5-FU, LV and oxalipla-
tin (FOLFOX), with or without Bev, was evaluated in 
previously untreated patients with mCRC. Although the 
difference in PFS and OS (both 1.4 mo) was statistically 
significant for treatment with Bev and Oxaliplatin based 
combinations compared to CTX alone, the additional 
benefit in PFS and OS was smaller for the oxaliplatin 
based regimen than that achieved in the study of  Hurwitz 
et al[5] (4.4 mo and 4.8 mo, respectively). Another Phase-
Ⅲ trial performed by Hochster et al[9], the TREE study, 
investigated the tolerability of  oxaliplatin in combination 
with 3 different 5-FU regimens (continuous infusion, bo-
lus and oral) with (TREE-2 cohort) or without (TREE-1 
cohort) Bev as a first-line therapy for mCRC. The study 
showed a benefit in overall response (52% vs 41%), PFS 
(9.9 mo vs 8.7 mo) and OS (24.6 mo vs 19.2 mo) in pa-
tients treated with FOLFOX6 + Bev compared to CTX 
Hohla F et al . Targeted treatment strategies in colorectal cancer
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alone. The addition of  Bev to second-line CTX with 
FOLFOX4, after progression on a CTX regimen without 
Bev, was evaluated in the ECOG E3200 Phase Ⅲ trial[11]. 
The addition of  Bev to FOLFOX4 improved response 
rates, PFS and OS in patients whose tumors had already 
progressed on irinotecan-containing CTX. These find-
ings led to the approval of  Bev in combination with CTX 
as second-line therapy for mCRC. The first randomized 
Phase Ⅲ trial which investigated the efficacy of  Bev ther-
apy continuation beyond progression was the ML18147 
(TML) study performed by Bennouna et al[12]. In this trial, 
patients with mCRC who progressed after a Bev con-
taining first-line CTX were randomly assigned to Bev + 
CTX and CTX alone. Continued use of  Bev in combina-
tion with a standard 2nd line CTX showed a modest but 
significant benefit in PFS (5.7 mo vs 4.1 mo, P = 0.0001) 
and OS (11.2 mo vs 9.8 mo) compared to CTX alone. 
Aflibercept
Aflibercept is a recently developed, multiple angiogenic 
factor trap that prevents not only VEGF-A, but also two 
additional members of  the VEGF family, VEGF-B and 
placental growth factor (PlGF), from activating their na-
tive receptors (VEGFR-1)[13,14]. These findings suggest 
that upregulation of  PlGF and VEGF-B with concurrent 
activation of  VEGFR-1 could be a potential mechanism 
of  tumor resistance to therapies such as Bev, which tar-
gets VEGF-A only[15-17]. The VELOUR trial evaluated 
aflibercept plus FOLFIRI vs FOLFIRI alone in patients 
with mCRC after progression on an oxaliplatin based 
CTX trial[18]. Addition of  Bev significantly improved PFS 
(6.9 mo vs 4.7 mo, P = 0.0007) and OS (13.5 mo vs 12.06 
mo) compared to CTX alone.
Regorafenib
Regorafenib is an inhibitor of  PDGF receptors, c-KIT, 
FGF receptor and VEGF1-3[19]. In the pivotal Phase Ⅲ 
study, CORRECT, patients with mCRC who had pro-
gressed after all approved drugs were randomly assigned 
to Regorafenib or placebo[20]. Treatment with Rego-
rafenib significantly prolonged OS (6.4 mo vs 5.0 mo, P 
= 0.0052) and PFS (1.9 mo vs 1.7 mo, HR = 0.49) com-
pared to placebo. 
EGFR TARGETING MABS
Cetuximab
Cetuximab is a recombinant, chimeric, human/murine 
immunglobulin (Ig)G1 mAb that binds specifically to 
the extracellular domain of  EGFR in normal and tumor 
cells, promoting receptor internalization and degradation 
without receptor phosphorylation and activation[21]. The 
most relevant clinical studies with cetuximab in combina-
tion with CTX are summarized in Table 2. In the pivotal 
Phase Ⅱ study, BOND, Cunningham et al[22] randomly 
assigned patients with mCRC, who where refractory to 
irinotecan based CTX, to either irinotecan and cetuximab 
or cetuximab alone. The combination of  irinotecan with 
cetuximab significantly improved overall response (22.9% 
vs 10.8%), median PFS (4.1 mo vs 1.5 mo) and OS (8.6 
mo vs 1.5 mo) compared to cetuximab alone. These find-
ings led to the approval of  cetuximab for patients with 
irinotecan refractory CRC, in the United States and Eu-
rope, as well as patients who were refractory to other pre-
vious therapies. Several small, retrospective studies have 
shown an association between KRAS mutation status and 
responsiveness of  a colorectal tumor to cetuximab[23-26]. 
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Table 1  Effect of bevacizumab in phase Ⅲ Studies in patients with metastatic colorectal cancer
Study Treatment Phase Regimen Patients (n ) Overall response Median PFS Median OS
(mo) (mo)
Hurwitz et al[5], First-line 3 IFL + Bev 402    45% 10.6 20.3
AVF2107 trial, vs
2004 Placebo 411    35%   6.2 15.5
P = 0.004 P < 0.001 P < 0.001
Fuchs et al[6], First-line 3 FOLFIRI (period 1) 144    47%   7.6 23.1
BICC-C trial, FOLFIRI + Bev (period 2)   57 54.4% 11.2 28.0
2007
Saltz et al[10], First-line 3 FOLFOX-4 or XELOX + Placebo 701    38%   8.0 19.9
N016966 trial, vs
2008 FOLFOX-4 or XELOX + Bev 699    38%   9.4 21.3
P = 0.0023 P = 0.077
Hochster et al[9], First-line 3 mFOLFOX-6   69    41%   8.7 19.2
TREE1/2 study, XELOX   48    27%   5.9 17.2
2008 mFOLFOX-6 + Bev   71    52%   9.9 26.1
XELOX + Bev   72    36% 10.3 24.6
Giantonio et al[11], Second-line 3 FOLFOX + Bev 290 22.7%   7.3 12.9
ECOG E3200, Placebo 289   8.6%   4.7 10.8
2007 P < 0.0001 P = 0.0011
Bev beyond  progression Second-line 3 Continued use of Bev + standard 409   5.4%   5.7 11.2
Bennouna et al[12], 2nd-line CTX vs 2nd-line CTX alone 411   3.9%   4.1   9.8
ML18147 (TML),
2012 P = 0.3113 P = 0.0001 P = 0.0062
IFL: Irinotecan/bolus 5-FU/leuvovorin; Bev: Bevacizumab; PFS: Progression free survival; OS: Overall survival; CTX: Chemotherapy. 
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randomly assigned to FOLFIRI plus either Cetuximab 
or Bev. Patients in the cetuximab and Bev arms had simi-
lar times to disease progression (10 mo vs 10.3 mo), but 
those treated with cetuximab had a significant improved 
OS (28.7 mo vs 25 mo, HR = 0.77, P = 0.01). 
Panitumumab
Panitumumab (Vectibix®) is a fully human, recombinant 
IgG2 mAB that binds specifically and with high affin-
ity to the extracellular domain of  EGFR in normal and 
tumor cells. Through competitive binding to EGFR 
ligands, panitumumab prevents EGFR dimerization, 
autophosphorylation and signaling, thereby inhibiting 
proliferation and promoting apoptosis[32]. The most rel-
evant clinical studies with panitumumab in combination 
with CTX are summarized in Table 3. In a phase-3 trial 
Van Cutsem et al[33] randomly assigned patients refractory 
to standard treatment, to treatment with panitumumab 
and BSC vs BSC alone. Objective response rates favored 
panitumumab over BSC (10% vs 0%). Panitumumab 
significantly prolonged PFS (8 wk vs 7.3 wk, HR = 0.54) 
but did not influence OS (HR = 1.00). A Phase Ⅲ study, 
PRIME, evaluated the combination of  panitumumab 
with FOLFOX4 vs FOLFOX4 alone as first-line treat-
ment of  metastatic CRC[34]. The combination therapy 
significantly improved PFS compared to CTX alone in 
patients with KRAS wild type (9.6 mo vs 8.0 mo, P = 
In the study of  Karapetis et al[27] patients with mCRC 
refractory to standard treatment were randomly assigned 
to receive Cetuximab plus best supportive care (BSC) or 
BSC alone, to detect activating mutations in exon 2 of  
the KRAS gene. Patients with tumors expressing mutant 
KRAS did not respond to cetuximab (overall response 
rate 1.2%), whereas patients with tumors harboring a 
wild-type KRAS did benefit from cetuximab compared 
to BSC alone in terms of  overall response rate (12.8% vs 
0%), PFS (3.7 mo vs 1.9 mo, HR = 0.4, P < 0.001) and 
OS (9.5 mo vs 4.8 mo, HR = 0.55, P < 0.001). In the 
patient cohort receiving BSC alone, the mutation status 
of  the KRAS gene was not significantly associated with 
OS (HR = 1.01)[27]. Retrospective analysis of  the KRAS 
status in the CRYSTAL trial has recently shown statisti-
cally significant differences between patients with wild-
type KRAS and those with mutant KRAS in response 
to FOLFIRI plus cetuximab in terms of  PFS (9.9 mo vs 
7.6 mo) and overall response (59% vs 36%)[28]. In KRAS 
wild-type patients, treatment of  mCRC patients with 
FOLFIRI plus cetuximab vs FOLFIRI alone significantly 
prolonged OS (24.9 vs 21.0, HR = 0.84)[28]. Data from the 
OPUS trial showed that the combination of  cetuximab 
and FOLFOX4 has an overall response rate of  61% 
in patients with wild-type KRAS compared with 33% 
in those with mutant KRAS[29,30]. In the Phase Ⅲ study 
FIRE-3 by Heinemann et al[31], patients with mCRC were 
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Table 2  Effect of cetuximab in phase Ⅱ/Ⅲ studies in patients with metastatic colorectal cancer
Study Treatment Phase Regimen Patients (n ) Overall 
response
Median PFS 
(mo)
Median OS 
(mo)
Cunnigham et al[22], Refractory to 
irinotecan
2 Irinotecan+ 218 22.90%   4.1   8.6
BOND study, cetuximab
2004 vs
cetuximab alone 211 10.80%   1.5   1.5
P = 0.0074 P < 0.0001 P = 0.48
Van Cutsem et al[28], First-line 3 FOLFIRI + cetuximab 105 36.20%   7.6 17.5
CRYSTAL trial, vs
2009 placebo   87 40.20%   8.1 17.7
(K-Ras mutant) OR = 0.80 HR = 1.07 HR = 1.03
P = 0.75
FOLFIRI + cetuximab 172 59.30%   9.9 24.9
vs
placebo 176 43.20%   8.7 21.0
(K-Ras wild-type) OR = 1.91 HR = 0.68 HR = 0.84
P = 0.004 P = 0.048
Bokemeyer et al[29,30], First-line 2 FOLFOX + cetuximab   52      33%   8.6 NR
OPUS trial, vs
2008 placebo   47      49%   5.5 NR
(K-Ras mutant) OR = 0.507 HR = 1.83
P = 0.106 P = 0.0192
FOLFOX + cetuximab   61      61%   7.7 NR
vs
placebo   73      37%   7.2 NR
(K-Ras wild-type) OR = 2.54 HR = 0.57
P = 0.011 P = 0.016
Heinemann et al[31], First line 3 FOLFIRI + cetuximab 297      62% 10.3 28.7
FIRE-3, FOLFIRI + bevacizumab 295      57% 10.4 25.0
2013 OR = 1.249 HR = 1.04 HR = 0.77
P = 0.18 P = 0.69 P = 0.017
PFS: Progression free survival; OS: Overall survival; NR: Not reported.
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0.02) and increased overall response rates (55% vs 48%). 
A non-significant increase in OS was also observed for 
panitumumab-FOLFOX4 vs CTX alone (23.9 mo vs 19.7 
mo, respectively, P = 0.072). Peeters et al[35] randomly as-
signed patients with mCRC pretreated with one CTX, to 
panitumumab plus FOLFIRI vs FOLFIRI alone. In wild-
type KRAS exon 2 mCRC patients a significant improve-
ment in PFS (5.9 mo vs 3.9 mo, P = 0.004) and response 
rates (35% vs 10%) was observed with the addition of  
panitumumab compared to CTX alone. In patients with 
mutant KRAS exon 2, there was no difference in effi-
cacy. In order to assess the efficacy and safety of  panitu-
mumab plus FOLFOX4 as compared with FOLFOX4 
alone according to the KRAS (exon 2-4) and NRAS 
(exon 2-4) mutation status data of  the PRIME study 
were updated[36]. In patients without any RAS mutation 
(KRAS 2-4/NRAS exon 2-4 wild-type) treatment with 
panitumumab significantly prolonged PFS (10.1 mo vs 7.9 
mo, P = 0.004) and OS (26.0 mo vs 20.2 mo, P = 0.043) 
compared to CTX alone. In the trial designated PEAK, 
Schwartzberg et al[37] randomly assigned untreated patients 
with mCRC to FOLFOX4 plus either panitumumab or 
Bev. Again, RAS status was assessed. In RAS wild-type 
stratum combination of  panitumumab with FOLFOX4 
improved PFS (13.5 mo vs 9.5 mo, HR = 0.65, P = 0.03) 
and OS (HR = 0.61, P = 0.09) compared to Bev with the 
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Table 3  Effect of panitumumab in phase Ⅲ studies in patients with metastatic colorectal cancer
Study Treatment Phase Regimen Patients 
(n )
Overall response Median PFS 
(mo)
Median OS 
(mo)
Van Cutsem et al[33], Refractory to 
standard CTX
3 Panitumumab + BSC 231 10%
2007 vs
BSC 232   0% HR = 0.54 HR = 1.0
P < 0.0001
Douillard et al[34], First-line 3 K-Ras WT
PRIME-trial, FOLFOX4 + panitumumab 325 55%   9.6 23.9
2010 FOLFOX4 331 48%   8.0 19.7
OR = 1.35 HR = 0.8 HR = 0.83
P = 0.068 P = 0.02 P = 0.072
K-Ras MT
FOLFOX4 + panitumumab 221 40%   7.3 15.5
FOLFOX 219 40%   8.8 19.3
HR = 1.29 HR = 1.24
P = 0.02 P = 0.068
Peeters et al[35], Second-line 3 K-Ras WT
2010 FOLFIRI + panitumumab 303 35%   5.9 14.5
FOLFIRI 294 10%   3.9 12.5
P = 0.001 HR = 0.73 HR = 0.85
P = 0.004 P = 0.12
K-Ras MT
FOLFIRI + panitumumab 238 13%   5.0 11.8
FOLFIRI 248 14%   4.9 11.1
HR = 0.85 HR = 0.94
P = 0.14
Douillard et al[36], First-line 3 K-Ras WT/MT other Ras
Update FOLFOX4 + panitumumab   51 NR   7.3 17.1
Prime-trial, FOLFOX4   57 NR   8.0 18.3
2013 HR = 1.28 HR = 1.29
P = 0.326 P = 0.305
K-Ras + N-Ras WT
FOLFOX4 + panitumumab 259 NR 10.1 26.0
FOLFOX 253 NR   7.9 20.2
HR = 0.72 HR = 0.78
P = 0.004 P = 0.043
Schwartzberg et al[37], First-line 2 K-Ras WT/MT other RAS Not
PEAK-trial, mFOLFOX6 + panitumumab 142 NR 10.9 Reached
2013  mFOLFOX6 + bevacizumab 143 NR 10.1 25.4
HR = 0.87 HR = 0.72
P = 0.35 P = 0.14
K-Ras / N-RAS WT Not 
mFOLFOX6 + panitumumab 
mFOLFOX6 + bevacizumab
88 NR 13.0 Reached
82 NR   9.5 29.0
HR = 0.65 HR = 0.61
P = 0.03 P = 0.09
PFS: Progression free survival; OS: Overall survival; BSC: Best supportive care; CTX: Chemotherapy; WT: Wild-type; MT: Mutant; NR: Not reported.
Hohla F et al . Targeted treatment strategies in colorectal cancer
same combination. 
ANTIPROLIFERATIVE EFFECT OF BN/GRP 
ANTAGONISTS IN CRC
In addition to polypeptide growth factors, such as EGF 
family members, much evidence supports the autocrine 
involvement of  specific neuropeptides, such as gastrin-re-
leasing peptide (GRP), in the proliferation, local invasion, 
metastasis and angiogenesis of  many tumors including 
CRC[38-42]. GRP is a member of  the bombesin (BN)-like 
peptide family and normally functions as a gastrointesti-
nal hormone and neurotransmitter[43]. From an oncologic 
point of  view, GRP affects the growth and differentiation 
of  a number of  human tumors including CRC[3,40,41,44-46]. 
Four receptor subtypes associated with the BN-like pep-
tide family have been identified and cloned[38,47]. Receptor 
subtype 1, termed GRP-R, binds BN and GRP with high 
affinity. Subtype 2 prefers neuromedin B and subtype 3 is 
classified as an orphan receptor because its natural ligand 
is not yet identified. A fourth subtype has a higher af-
finity for amphibian BN than for GRP. These receptors 
are coupled to G-protein via their intracellular domains 
and, thus, belong to the G-protein receptor superfam-
ily. Studies have shown that receptors for GRP (GRP-
Rs) are overexpressed in human CRC and human CRC 
cell lines when compared with normal colonic epithelial 
cells[48-55]. Approaches to inhibit the autocrine growth ef-
fect of  GRP-like peptides on tumor growth in human 
and animal studies include receptor antagonists, mono-
clonal antibodies, vaccination against GRP, antisense 
oligonucleotides or bispecific molecules[56]. During the 
past decade, a large number of  BN/GRP antagonists 
were synthesized in our laboratories. Among these com-
pounds were RC-3095 and RC-3940-Ⅱ, both of  which 
showed strong inhibitory effects on several experimental 
cancers including CRC in vitro and in mouse xenografts 
in vivo[40,41,54,57-60]. The tumor-inhibitory mechanism of  
BN/GRP antagonists appears to be more complex than 
a simple competitive action on the receptor and is incom-
pletely understood[40,56]. In xenografts of  HT-29 human 
CRC inhibition of  tumor growth by BN/GRP antago-
nist, RC-3095, was linked with a significant down-regu-
lation of  EGF receptors[61]. In another experiment we 
showed that combined treatment with RC-3940-Ⅱ and a 
chemotherapeutic agent, such as 5-FU or irinotecan, re-
sulted in a synergistic growth inhibition of  experimental 
human colon cancers xenografted into nude mice[54]. Cell 
cycle analysis of  in vitro material revealed that BN/GRP 
antagonist, RC-3940-Ⅱ, led to an increase in the number 
of  cells blocked in S and G2/M phase and fewer cells 
with G0/G1 DNA content[54]. A Phase Ⅰ clinical trial with 
BN/GRP antagonist, RC-3095, in 25 heavily pretreated 
patients with advanced solid malignancies, including 2 pa-
tients with mCRC, showed no objective tumor response 
at the dosage used[62]. In conclusion, BN/GRP antago-
nists have shown impressive preclinical antitumor activity 
and should be further investigated in clinical trials. 
ANTIPROLIFERATIVE EFFECT OF GHRH 
ANTAGONISTS IN CRC
Growth hormone-releasing hormone (GHRH) belongs 
to the family of  related peptides that includes: vasoac-
tive intestinal polypeptide (VIP), pituitary adenylate 
cyclase-activating peptide (PACAP), secretin and gluca-
gon[63]. GHRH released by the hypothalamus, regulates 
the secretion of  growth hormone (GH) by binding to 
specific receptors for GHRH (GHRH-R) in the pitu-
itary gland[40,41,64]. In turn, GH induces the production 
of  hepatic insulin-like growth factor (IGF-1), which is 
a known mitogen and has been linked with malignant 
transformation, tumor progression, and tumor metasta-
sis[65]. In addition to its neuroendocrine action, GHRH 
functions as an autocrine/paracrine growth factor in vari-
ous cancers, including CRC[40,66]. Antagonistic analogs of  
GHRH, developed our laboratories, strongly suppress 
the growth in vitro and in vivo of  many experimental can-
cers including CRC[40,41,54,64,66-68]. The antitumor effects of  
GHRH antagonists were initially thought to be exerted 
only indirectly through the inhibition of  serum IGF-
Ⅰ levels. However, evidence suggested, that the principal 
antiproliferative effects of  GHRH antagonists are exerted 
directly through the blocking of  the stimulatory loop 
formed by GHRH and its receptors on tumor cells. Our 
group demonstrated the presence of  the pituitary type 
GHRH-receptor and four truncated splice variants (SVs) 
of  GHRH-R in human cancer specimens and cancer cell 
lines including CRC[40,66,69,70]. Of  the four isoforms, SV1 
has the greatest structural similarity to the GHRH-R and 
it probably mediates, in concert with GHRH-R, the effect 
of  GHRH and its antagonists on tumors. We also exam-
ined the protein and mRNA expression of  GHRH-R and 
SV1 in normal human tissues and human CRC tissue by 
immunohistochemical staining and RT-PCR[70]. The main 
finding was that the expression of  GHRH-R and SV1 
was absent in normal colonic mucosa but significantly 
increased in tubulovillous adenomas and in colorectal 
cancers. We assume that this aberrant expression of  
GHRH-R and SV-1 in colorectal cancers may provide 
a molecular target for a therapeutic approach based on 
GHRH antagonists[70]. We showed that GHRH antago-
nist, JMR-132, significantly decreased the volume of  
HT-29, HCT-116, and HCT-15 experimental human co-
lon carcinomas grown as xenografts in athymic nude mice 
by up to 75% and also extended tumor doubling times 
compared to controls[67]. In other studies, combined treat-
ment in vivo with JMR-132 plus chemotherapeutic agents 
5-FU, irinotecan or cisplatin resulted in an additive tumor 
growth suppression of  HT-29, HCT-116 and HCT-15 
human colon cancer xenografts[68]. Cell cycle analysis re-
vealed that treatment of  HCT-116 human colon cancer 
cells with GHRH antagonist, JMR-132, in vitro was ac-
companied by a cell cycle arrest in S-phase. Thus, we sug-
gest that JMR-132 enhances antiproliferative effects of  
S-phase specific cytotoxic drugs by causing accumulation 
of  tumor cells in S-phase[68]. The molecular mechanisms 
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involved in the antiproliferative effects of  GHRH antago-
nists on tumor cells have not been completely elucidated. 
We showed in HCT-116 human colon cancer cells in vitro, 
that treatment with GHRH antagonist, JMR-132, causes 
significant DNA damage as measured by an increase in 
olive tail moment and loss of  inner mitochondrial mem-
brane potential. Western blotting demonstrated a time-
dependent increase in protein levels of  phosphorylated 
p53(Ser46), Bax, cleaved caspase-9, -3, cleavage of  PARP 
and a decrease in Bcl-2 levels[67]. Also, an augmentation in 
cell cycle checkpoint protein p21Waf1/Cip1 was accompanied 
by a cell cycle arrest in S-phase. DNA fragmentation visu-
alized by the comet assay and by the number of  apoptotic 
cells increased time dependently as determined by flow 
cytometric annexin-V and PI staining assays. Thus we 
suggest that GHRH antagonists exert their antiprolifera-
tive effects on experimental colon cancer cells through 
p21Waf1/Cip1 mediated S-phase arrest along with apoptosis 
involving the intrinsic pathway[67]. So far GHRH antago-
nists have not been clinically tested. However, the impres-
sive preclinical activity merits further investigations in 
clinical trials. 
ANTIPROLIFERATIVE EFFECT 
OF CYTOTOXIC ANALOGS OF 
SOMATOSTATIN, BN/GRP AND LHRH IN 
CRC
On the basis of  the presence of  specific receptors for hy-
pothalamic peptides on various human cancers including 
CRC, our group developed targeted cytotoxic analogs of  
somatostatin (SST) and LHRH linked to doxorubicin or 
2-pyrrolinodoxorubicin[71,72]. 
Cytotoxic somatostatin analogs, AN-238 and AN-162
The hypothalamic neuropeptide SST exists in two main 
active forms: a 14-amino acid peptide and an amino ter-
minally extended version consisting of  28 amino acids[41]. 
Both forms are present in the gastrointestinal tract inhib-
iting the secretion of  many hormones including growth 
hormone, insulin, glucagon, gastrin, secretin and chole-
cystokinin[41]. At least five distinct SST receptor subtypes, 
SSTR1-5, have been characterized[73,74]. These receptors 
are distributed in both normal and cancerous tissues, 
but found in higher density in the latter as well specifi-
cally as in human colon cancer cell lines[40,41,75,76]. While 
native SST shows high affinities to SSTR1-5, synthetic 
octapeptides such as RC-160 and RC-121, synthesized in 
our laboratory, bind preferentially to SSTR2 and SSTR5, 
moderately affinity to SST3 and with low affinity to SST1 
and SST4[40,73,74,77]. In our endeavour to develop chemo-
therapy targeted to SSTR, we synthesized two cytotoxic 
hybrids of  SST, AN-238, AN-162, containing DOX or 
the strongly active derivative of  DOX, 2-pyrrolino-DOX, 
the latter conjugated to the octapeptide SST analog, 
RC-121[78]. Both cytotoxic analogs AN-238 (containing 
2-pyrrolino-DOX) and AN-162 (containing DOX), sig-
nificantly inhibited tumor growth of  experimental human 
colon cancer xenografted into nude mice[75,76]. Cell cycle 
analysis showed that treatment of  HCT-116 human colon 
cancer cells with AN-162 caused a significantly greater in-
crease in the number of  S-phase cells and apoptotic cells 
as compared to treatment with doxorubicin alone[75]. We 
hypothesize that the lesser effect of  unconjugated doxo-
rubicin compared to AN-162 could be the reduction of  
intracellular drug accumulation caused by increased drug 
efflux when Dox alone is used. Cellular resistance (multi 
drug resistance, MDR) to doxorubicin is often related 
to its rapid efflux from the intracellular environment by 
membrane transporters termed p-glycoproteins (Pgp), 
products of  the multiple drug resistance gene 1 (MDR-1). 
To proof  this concept, we treated the doxorubicin re-
sistant mouse leukemic cell line P388/R84, which over-
expresses the membrane transporter Pgp, with AN-162 
and compared to unconjugated doxorubicin. Cell cycle 
analysis revealed that AN-162 compared to doxorubicin 
caused a progressive accumulation of  P388/R84 cells in 
S and G2 phase with an increase in the number of  apop-
totic cells with < G0/G1 content[75]. Thus, treatment ef-
ficacy with targeted cytotoxic peptides may be related to 
overcoming chemoresistance. 
Cytotoxic LH/RH analogs
The hypothalamic hormone, LHRH, also known as 
gonadotropin-releasing hormone is the primary regulator 
of  gonadal function and reproduction in vertebrates[79]. 
Receptors for LHRH have been demonstrated in healthy 
sex organs, as well as in breast, ovarian, endometrial and 
prostate cancers and cell lines of  colorectal cancer[71,72,80]. 
On the basis of  the presence of  receptors for LHRH on 
these tumors, we have developed a new class of  targeted 
antitumor agents, AN-152 (AEZS-108) and AN-207, by 
linking cytotoxic radicals to LHRH agonists[72]. Thus Dox 
was coupled to LHRH to form the targeted cytotoxic an-
alog AN-152 (AEZS-108). An even more potent hybrid 
molecule, AN-207, was synthesized by conjugating 2-pyr-
rolino-Dox to LHRH. Both cytotoxic LHRH analogs, 
AN-152 and AN-207, powerfully inhibited growth of  ex-
perimental colon cancers xenografted into nude mice[80]. 
AN-152 (AEZS-108) has been successfully tested in one 
Phase Ⅰ and two Phase Ⅱ studies in patients with heavily 
pretreated LHRH-R positive recurrent ovarian and endo-
metrial cancers[71]. Phase Ⅰ/Ⅱ studies with AEZS-108 in 
castration-resistant prostate cancer and refractory bladder 
cancer are presently in progress with promising results[71]. 
In our experimental studies, all 5 human CRC cell lines 
evaluated expressed LHRH receptors[80]. Currently, there 
are no clinical data on the expression of  LBHRH recep-
tors in CRC. However, a common practice in clinical 
trials with cytotoxic LHRH analog AN-152 on prostatic, 
bladder, ovarian and endometrial cancers is to first evalu-
ate the expression of  the LHRH receptor in the tumors 
of  patients by immunohistochemistry. Cytotoxic LHRH 
analog, AEZS-108, may be a useful agent for the treat-
ment of  LHRH receptor positive advanced colorectal 
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carcinoma. On the basis of  our results, patients with 
mCRC could be considered for the inclusion in future 
clinical trials with cytotoxic LHRH analog AEZS-108, 
after establishing the presence of  LHRH receptors in bi-
opsy samples. 
CONCLUSION
The current management of  mCRC involves various 
active drugs, either in combination or as single agents: 
5-FU/LV, capecitabine, irinotecan, oxaliplatin, bevaci-
zumab, aflibercept, regorafenib, cetuximab and panitu-
mumab. The choice of  therapy is based on consideration 
of  the goals of  therapy, the type and timing of  prior ther-
apy, the different toxicity profiles of  the constituent drugs 
and the molecular characteristics of  the tumor. Treatment 
regimens with Bev are independent of  the RAS mutation 
status and show greater response rates, up to 10%, and 
significantly longer PFS and OS in combination with an 
irinotecan based CTX. Treatment of  Bev with oxaliplatin 
based regimens seems to have a more moderate benefit 
in PFS and OS. Beyond progression after a Bev contain-
ing regimen, continued use of  Bev in combination with 
a standard second-line CTX significantly improves PFS 
and OS. Bev or aflibercept, when given with second-line 
CTX, have comparable outcomes, each adding 1.4 mo of  
survival time. Regorafenib has been approved as a treat-
ment option for patients with good performance status 
and who have received all available agents leading to a 
modest OS advantage of  1.4 mo. Recently published data 
from the FIRE-3, PRIME and the PEAK trial suggest, 
that cetuximab based regimens may lead to improved 
OS compared to Bev containing regimens. The observed 
survival benefit of  EGFR targeting agents may be par-
tially a result of  excluding patients with mutated RAS 
metastatic colorectal cancers as performed in the PEAK 
trial and the updated PRIME study. Therefore, especially 
for patients with RAS wild-type mCRC a cetuximab-
based treatment may be more beneficial and should be 
offered as first line therapy. However, response to treat-
ment is usually temporary in patients with mCRC and 
leads to a median survival of  24 mo. Thus receptors for 
certain peptide hormones, which are highly expressed in 
CRC, may be investigated as therapeutic targets. Targeted 
cytotoxic LHRH analog AN-152 (AEZS-108), should be 
examined for treatment of  patients with LHRH receptor 
positive CRC. 
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